Insights Into Acute Lymphoblastic Leukemia (ALL)
Perspectives of community physicians on the treatment of ALL
National – June 24, 2024
Faculty Chair
Michael R. Grunwald, MD, FACP
Atrium Health Levine Cancer Institute, Charlotte, NC, USA
South – July 18, 2024
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Mid-Atlantic (FL, AL, GA) – July 23, 2024
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
West (California) – July 25, 2024
Faculty Chair
Aaron Logan, MD, PhD
University of California, San Francisco, CA, USA
More Information
- Virtual series
- California, Nevada, Texas, New Mexico, Indiana, Ohio, New York, New Jersey, Maryland
More Information
- Virtual series
- Texas
More Information
- Virtual series
- Alabama, Florida, Georgia
More Information
- Virtual series
- California
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of ALL
- Disease state and data presentations were developed in conjunction with a national or regional oncology expert
- Insights on the following therapies were obtained: blinatumomab, ponatinib, inotuzumab ozogamicin, liposomal vincristine, and chimeric antigen receptor (CAR) T-cell therapy
GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprised 10–15 medical oncologists representative of each region
